PolyPid Ltd. (NASDAQ:PYPD) Short Interest Down 13.4% in January

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 21,900 shares, a decline of 13.4% from the December 31st total of 25,300 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average daily volume of 28,600 shares, the short-interest ratio is currently 0.8 days.

PolyPid Trading Down 4.3 %

Shares of PYPD traded down $0.13 during trading hours on Friday, reaching $2.86. The stock had a trading volume of 35,395 shares, compared to its average volume of 24,325. PolyPid has a 52 week low of $2.37 and a 52 week high of $7.00. The firm has a 50-day moving average of $3.08 and a 200 day moving average of $3.35. The company has a market cap of $13.73 million, a P/E ratio of -0.37 and a beta of 1.32. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17.

Institutional Trading of PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Stonepine Capital Management LLC acquired a new stake in PolyPid Ltd. (NASDAQ:PYPD) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned approximately 2.89% of PolyPid at the end of the most recent quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright decreased their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, December 26th. RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a research note on Tuesday. Craig Hallum began coverage on PolyPid in a research report on Monday, November 4th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Rodman & Renshaw initiated coverage on shares of PolyPid in a research report on Tuesday. They set a “buy” rating and a $13.00 target price on the stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.